The approvals in June of two gene therapies, Elevidys and Roctavian, indicated for Duchenne muscular dystrophy and hemophilia A, respectively, could be a harbinger for a record-setting year in the cell and gene therapy space.However, the ever-increasing numbers of cell and gene therapy candidates in the pipeline, along with a steady growth of new approvals, […]
